A Clinical study of NKT cell activation immunotherapy for head and neck pharyngeal squamous cell carcinoma

A Clinical study to evaluate the therapeutic safety and anticancer efficacy of a-Galactosylceramide pulsed CD14- positive cells(SB-ImmuneAllcure-HN) for NKT cell activation immunotherapy in patients with pharyngeal squamous cell carcinoma of the head and neck.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0011122

Enrollment

Registered

2025-11-10

Start date

2025-12-01

Completion date

Unknown

Last updated

2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Biological/Vaccine, Non-Stem Cell : [SB-ImmunoCure-HN] Eligibility criteria: Subjects who meet the inclusion/exclusion criteria of the study and provide written informed consent Treatment: Administr

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients aged between 18 and 90 years with a diagnosis of pharyngeal squamous cell carcinoma of the head and neck. 2. Patients with ECOG performance status 0-2 and an expected survival of =6 months. 3. Patients who have not received chemotherapy or radiotherapy for a minimum of 4 weeks.

Exclusion criteria

Exclusion criteria: 1. Patients confirmed to be pregnant or breastfeeding. 2. Patients enrolled in other clinical studies or trials. 3. Patients deemed unsuitable by the principal investigator for other reasons.

Design outcomes

Primary

Measure	Time frame
Tumor Response Rate, ORR;Progression Free Survival, PFS;Common Terminology Criteria for Adverse Events Version 4.0 (CTCAE v4.0)	—

Secondary

Measure	Time frame
Measurement of Visible Lesions Size;Measurement of invisible lesions of organs or cervical lymph nodes	—

Countries

Korea, Republic of

Contacts

Public ContactLEE DONGHOON

Chonnam National University Hospital Hwasun Hospital

leen3l@daum.net+82-61-379-8190

Outcome results